Hong Kong's healthcare system undergoes reform to make life-saving leukaemia treatment accessible to 400 patients at a fraction of the original cost
Original framing: “Hongkongers to pay only HK$240 a year for leukaemia drug after system shake-up” — South China Morning Post
Hong Kong's healthcare system has a complex history, with the city's colonial past and subsequent handover to China influencing the development of its healthcare infrastructure. The government's decision to subsidise Dasatinib can be seen as a response to growing public pressure and advocacy from cancer patients and their families, who have been pushing for change since the 1990s.
The government's decision to subsidise Dasatinib marks a significant shift in Hong Kong's healthcare policy, prioritising patient affordability and access to life-saving treatments.
However, this move is just one step towards a more comprehensive and equitable healthcare system. To truly address the challenges facing Hong Kong's healthcare system, the government must implement a range of solutions, including increasing transparency and accountability in healthcare pricing, implementing price controls and negotiating with pharmaceutical companies, investing in public health infrastructure and prevention programs, and establishing a patient-centered approach to healthcare. By working together, we can create a healthcare system that is truly accessible, affordable, and equitable for all.